Latigo Biotherapeutics (NASDAQ:LTGO) Stock Rating Raised to Hold at Wall Street Zen

Latigo Biotherapeutics (NASDAQ:LTGO) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday, Wall Street Zen reports.

Several other equities analysts have also weighed in on the stock. Guggenheim started coverage on shares of Latigo Biotherapeutics in a report on Tuesday, September 1st. They set a “buy” rating and a $50.00 target price for the company. Jefferies Financial Group started coverage on Latigo Biotherapeutics in a research report on Tuesday, September 1st. They issued a “buy” rating and a $50.00 target price for the company. Weiss Ratings assumed coverage on shares of Latigo Biotherapeutics in a research note on Tuesday. They set a “sell (e-)” rating for the company. Leerink Partners initiated coverage on Latigo Biotherapeutics in a report on Tuesday, September 1st. They set an “outperform” rating and a $36.00 price target for the company. Finally, The Goldman Sachs Group assumed coverage on shares of Latigo Biotherapeutics in a report on Tuesday, September 1st. They set a “buy” rating and a $73.00 target price for the company. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $52.25.

Latigo Biotherapeutics Trading Down 3.2%

LTGO opened at $12.60 on Friday. The company’s 50 day simple moving average is $17.95. Latigo Biotherapeutics has a twelve month low of $10.24 and a twelve month high of $25.93.

Latigo Biotherapeutics (NASDAQ:LTGO) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.55) earnings per share for the quarter.

Insider Buying and Selling

In other news, major shareholder Foresite Capital Management V, bought 140,000 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was bought at an average price of $18.00 per share, for a total transaction of $2,520,000.00. Following the completion of the transaction, the insider directly owned 2,008,024 shares in the company, valued at $36,144,432. The trade was a 7.49% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director James B. Tananbaum purchased 140,000 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was acquired at an average price of $18.00 per share, with a total value of $2,520,000.00. Following the completion of the transaction, the director owned 2,008,024 shares of the company’s stock, valued at $36,144,432. This represents a 7.49% increase in their position. The disclosure for this purchase is available in the SEC filing.

Key Stories Impacting Latigo Biotherapeutics

Here are the key news stories impacting Latigo Biotherapeutics this week:

• Positive Sentiment: Latigo reported a third-quarter loss of $0.55 per share, beating analyst estimates by $0.12. Earnings estimate beat
• Positive Sentiment: The company says Phase 3 bunionectomy and open-label safety trials for onzotrigine remain on track to begin, with topline results expected in the second half of 2027. Third-quarter results and business highlights
• Positive Sentiment: Latigo appointed pain-sector executive Todd Smith as president and CEO. His commercialization experience could support the company’s plans to advance and potentially commercialize non-opioid pain treatments. CEO appointment
• Neutral Sentiment: LTGO trading was temporarily paused twice under limit-up/limit-down volatility rules. The pauses indicate heightened volatility, not a specific direction or cause.
• Negative Sentiment: Despite beating estimates, Latigo still reported a quarterly loss, and the expected Phase 3 readout is not until the second half of 2027, leaving substantial time and clinical-development risk before a potential catalyst. Third-quarter and nine-month results

About Latigo Biotherapeutics

Latigo Biotherapeutics, Inc is a clinical-stage biopharmaceutical company developing non-opioid treatments for pain. The company focuses on therapies designed to selectively target Nav1.8, a sodium channel expressed in peripheral sensory neurons that plays an important role in the transmission of pain signals.

Latigo’s lead product candidate, LTG-001, is an oral, selective Nav1.8 inhibitor being developed for the treatment of acute and chronic pain conditions. By targeting pain signaling outside the central nervous system, the company aims to develop alternatives to opioid medicines and other pain treatments that may carry significant safety or tolerability concerns.